Additional file 1 of FGL1: a novel biomarker and target for non-small cell lung cancer, promoting tumor progression and metastasis through KDM4A/STAT3 transcription mechanism

Supplementary Material 1. Fig. S1. (A) Cell component comparison between single-cell samples in NSCLC using the CancerSCEM database. (B) Analysis of the correlation between FGL1 and OS using the Prognoscan database (GSE17710). (C) Analysis of the correlation between FGL1 and RFS using the Prognoscan database (GSE17710). (D) Scoring based on the intensity of FGL1 expression: 0 points for "negative", 1 point for "weak positive", 2 points for "positive", and 3 points for "strong positive". (E) Representative images of tissue slices from patients with lymph node stages of N0, N1, and N2. (F) According to lymph node staging, the expression of FGL1 was analyzed in 98 patients with cancer. **P < 0.01. (G) Representative images of tissue slices from patients with clinical stages I, II, and III. (H) According to the clinical staging, the expression of FGL1 was analyzed in 98 patients with cancer. *P < 0.05, **P < 0.01. (I) The expression of FGL1 protein was measured on five NSCLC cancer cell lines (A549, H1299, H1975, H460, and SPCA1). (J) The expression of FGL1 mRNA was measured on five NSCLC cancer cell lines (A549, H1299, H1975, H460, and SPCA1).